Advertisement
UK markets close in 7 hours 22 minutes
  • FTSE 100

    8,122.31
    +43.45 (+0.54%)
     
  • FTSE 250

    19,753.25
    +151.27 (+0.77%)
     
  • AIM

    755.63
    +2.51 (+0.33%)
     
  • GBP/EUR

    1.1659
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2517
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    51,415.27
    +270.08 (+0.53%)
     
  • CMC Crypto 200

    1,388.13
    -8.41 (-0.60%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.99
    +0.42 (+0.50%)
     
  • GOLD FUTURES

    2,356.90
    +14.40 (+0.61%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,672.69
    +388.15 (+2.25%)
     
  • DAX

    18,035.27
    +117.99 (+0.66%)
     
  • CAC 40

    8,041.83
    +25.18 (+0.31%)
     

Nektar’s NKTR-181 Expected to Transform Chronic Pain Market

Nektar Therapeutics (NKTR) plans to submit an NDA (New Drug Application) with the FDA (U.S. Food & Drug Administration) for late-stage chronic pain drug NKTR-118 by April 2018.